Context Therapeutics (CNTX) Projected to Release Earnings on Wednesday

Context Therapeutics (NASDAQ:CNTX) is projected to post its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03. On average, analysts expect Context Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Context Therapeutics Stock Performance

Shares of CNTX stock opened at $0.60 on Monday. Context Therapeutics has a 12 month low of $0.55 and a 12 month high of $3.62. The stock has a market cap of $55.07 million, a PE ratio of -1.43 and a beta of 1.74. The company’s fifty day moving average price is $1.08 and its 200-day moving average price is $1.95.

Analyst Ratings Changes

A number of brokerages recently issued reports on CNTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a research report on Friday, July 17th. Maxim Group dropped their price objective on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, June 16th. Finally, Wall Street Zen cut shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $6.17.

Institutional Investors Weigh In On Context Therapeutics

Institutional investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new stake in Context Therapeutics during the 4th quarter valued at about $43,000. Citadel Advisors LLC purchased a new stake in shares of Context Therapeutics during the third quarter valued at approximately $100,000. XTX Topco Ltd grew its holdings in shares of Context Therapeutics by 858.8% during the fourth quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after buying an additional 91,008 shares during the last quarter. State Street Corp increased its position in shares of Context Therapeutics by 8.5% during the fourth quarter. State Street Corp now owns 165,607 shares of the company’s stock valued at $243,000 after acquiring an additional 13,000 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Context Therapeutics by 58.8% during the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after acquiring an additional 188,202 shares in the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.